Fullerton Fund Management Co Ltd. Has $24.09 Million Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Fullerton Fund Management Co Ltd. reduced its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 13.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 31,202 shares of the company’s stock after selling 4,828 shares during the quarter. Eli Lilly and Company accounts for about 0.8% of Fullerton Fund Management Co Ltd.’s holdings, making the stock its 29th biggest position. Fullerton Fund Management Co Ltd.’s holdings in Eli Lilly and Company were worth $24,088,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in LLY. Highline Wealth Partners LLC grew its position in Eli Lilly and Company by 80.0% in the 4th quarter. Highline Wealth Partners LLC now owns 45 shares of the company’s stock worth $35,000 after purchasing an additional 20 shares in the last quarter. FPC Investment Advisory Inc. increased its position in shares of Eli Lilly and Company by 358.3% during the fourth quarter. FPC Investment Advisory Inc. now owns 55 shares of the company’s stock valued at $45,000 after acquiring an additional 43 shares during the last quarter. Prudent Man Investment Management Inc. bought a new stake in Eli Lilly and Company during the fourth quarter worth $48,000. Compass Financial Services Inc purchased a new position in Eli Lilly and Company in the fourth quarter worth $50,000. Finally, Fiduciary Advisors Inc. bought a new position in Eli Lilly and Company in the 4th quarter valued at $58,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analysts Set New Price Targets

LLY has been the subject of several research reports. UBS Group reduced their price target on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a “buy” rating for the company in a research report on Friday, May 2nd. Wells Fargo & Company restated an “overweight” rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. HSBC downgraded Eli Lilly and Company from a “buy” rating to a “reduce” rating and dropped their price objective for the company from $1,150.00 to $700.00 in a research note on Monday, April 28th. Berenberg Bank set a $970.00 target price on Eli Lilly and Company in a research report on Thursday, January 16th. Finally, The Goldman Sachs Group raised Eli Lilly and Company from a “neutral” rating to a “buy” rating and dropped their price target for the company from $892.00 to $888.00 in a research report on Tuesday, April 8th. One research analyst has rated the stock with a sell rating, two have given a hold rating and nineteen have assigned a buy rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average target price of $1,002.80.

Insider Transactions at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the business’s stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the sale, the chief accounting officer now owns 5,840 shares in the company, valued at $4,778,521.60. The trade was a 14.62 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 0.14% of the stock is currently owned by insiders.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $736.21 on Friday. The stock has a market cap of $697.73 billion, a price-to-earnings ratio of 62.87, a PEG ratio of 1.40 and a beta of 0.48. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. The business has a 50-day simple moving average of $810.98 and a 200 day simple moving average of $811.52. Eli Lilly and Company has a 52 week low of $677.09 and a 52 week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). The business had revenue of $12.73 billion for the quarter, compared to analysts’ expectations of $12.77 billion. Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The firm’s revenue for the quarter was up 45.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.58 EPS. On average, research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th will be given a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a dividend yield of 0.81%. The ex-dividend date of this dividend is Friday, May 16th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 48.82%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.